Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

NCT00121680 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00121680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2005
Completion date
May 31, 2015
Enrollment
115 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma